Referencia número: HY-B0144A

Pitavastatin

Name: Pitavastatin
Brand: MedChemExpress
SKU: HY-B0144A
Price: 42.00 USD
Availability: InStock
Rating: 5 (18 reviews)

(Synonyms: NK-104)

18 Cited Publications

Revisión del cliente

Based on 18 publication(s) in Google Scholar

Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 98.01%
No. CAS: 147511-69-1
Fòrmula: C₂₅H₂₄FNO₄
Peso molecular:421.46

Almacenamiento:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Pitavastatin Chemical Structure

No. CAS: 147511-69-1

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (18)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

HMG-CoA Reductase^[1]

In Vitro

Pitavastatin inhibits the growth of a panel of ovarian cancer cells, including those considered most likely to represent HGSOC, grown as a monolayers (IC₅₀=0.4-5 μM) or as spheroids (IC₅₀ = 0.6-4 μM)^[4].
Pitavastatin (1 μM; 48 hours) induces apoptosis, evidenced by the increased activity of executioner caspases-3,7 as well as caspase-8 and caspase-9 in Ovcar-8 cells and Ovcar-3 cells^[4].
Pitavastatin (1 μM, 48 hours) causes PARP cleavage in Ovcar-8 cells^[4].
Pitavastatin (0.1 and 1 μM; 1 h, then cells incubate with TNF-α for 6 h) increases the expression of ICAM-1 mRNA through suppressing NF-κB pathway in TNF-α-stimulated human saphenous vein endothelial cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:

Ovcar-8 cells
Concentration:

1 μM
Incubation Time:

48 hours
Result:

Induced PARP cleavage.

In Vivo

Pitavastatin (59 mg/kg; p.o.; twice daily for 28 days) causes significant tumour regression^[4].
Pitavastatin (0.1 mg/kg; p.o; daily for 12 weeks) retards the progression of atherosclerosis formation and improves NO bioavailability by eNOS up-regulation and decrease of O^2- in diet induced severe hyperlipidemia rabbit model^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

4 week old female NCR Nu/Nu female mice (bearing Ovcar-4 tumours)^[4]
Dosage:

59 mg/kg
Administration:

p.o.; twice daily for 28 days
Result:

Caused significant tumour regression.

Animal Model:

Female New Zealand white rabbits (diet induced severe hyperlipidemia)^[7]
Dosage:

0.1 mg/kg
Administration:

p.o; daily for 12 weeks
Result:

Retarded the progression of atherosclerosis formation and improved NO bioavailability by eNOS up-regulation and decrease of O^2-.

Chemical Information

No. CAS 147511-69-1
Appearance Solid
Peso molecular 421.46
Fòrmula C₂₅H₂₄FNO₄
Color White to off-white
SMILES

O=C(O)C[C@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4CC4
Synonyms

NK-104
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (18)

All PK/PD AnalysisBio/Physico-chemical AssayHistological Imaging/StainingCell Proliferation/Viability AssayMicrobiological AssayIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

J Hepatol

FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. [Abstract]

2021 Aug;75(2):363-376. PMID: 33887357
Cancer Res

TRAPPC4 Promotes GPX4 Stability to Drive Ferroptosis Resistance and Tumor Progression in Head and Neck Squamous Cell Carcinoma. [Abstract]

2026 Jul 15;86(14):3436-3458. PMID: 41974002
Nat Commun

2026 Oct 1.
Acta Pharm Sin B

Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease. [Abstract]

2020 May;10(5):850-860. PMID: 32528832

Pitavastatin purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 May;10(5):850-860. [Abstract]

Pharmacokinetic parameters of Pitavastatin (5 mg/kg; single dose) after oral administration.

Pitavastatin purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 May;10(5):850-860. [Abstract]

Pharmacokinetics of Pitavastatin (5 mg/kg; p.o.; single dose) in WT and KO rats. The concentrations of Pitavastatin were determined by LC–MS/MS.
Phytomedicine

2026 Sep 29:162:158838. PMID: 42843051
Antioxidants (Basel)

Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species. [Abstract]

2024 May 29;13(6):667. PMID: 38929106

Pitavastatin purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 May 29;13(6):667. [Abstract]

Pitavastatin Calcium (0.5-1 μM) makes FLC fungicidal.

Pitavastatin purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 May 29;13(6):667. [Abstract]

PIT (0-25 μM) confers fungicidal properties to voriconazole, ketoconazole, itraconazole, and miconazole.

Pitavastatin purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 May 29;13(6):667. [Abstract]

MIC assays and spotting assays show that erg11△/erg11△ was significantly sensitive to PIT (0-100 μM) compared to the wild-type strain.
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
Biochem Pharmacol

Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. [Abstract]

2019 Nov:169:113612. PMID: 31437461

Pitavastatin purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2019 Nov:169:113612. [Abstract]

Uptake ability of Pitavastatin (a human OATP1B1/1B3 substrate，0.1-10 μM; 1 h) by the control and rSlco1b2 overexpression cells. The rate was expressed as the relative intracellular substrate concentration (substrate/internal standard MS/MS response ratio).
Bioorg Chem

Dried tangerine peel polysaccharide (DTPP) alleviates hepatic steatosis by suppressing TLR4/MD-2-mediated inflammation and endoplasmic reticulum stress. [Abstract]

2024 Jun:147:107369. PMID: 38640721

Pitavastatin purchased from MedChemExpress. Usage Cited in: Bioorg Chem. 2024 Jun:147:107369. [Abstract]

Oil red O staining and quantification of zebrafish liver after treatment with DTPP and Pitavastatin Calcium. Day1 of DTPP treatment.

Pitavastatin purchased from MedChemExpress. Usage Cited in: Bioorg Chem. 2024 Jun:147:107369. [Abstract]

Oil red O staining and quantification of zebrafish liver after treatment with DTPP and Pitavastatin Calcium. Day3 of DTPP treatment.
Acta Biochim Biophys Sin (Shanghai)

Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis. [Abstract]

2024 Apr 25;56(4):621-633. PMID: 38516704

Pitavastatin purchased from MedChemExpress. Usage Cited in: Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):621-633. [Abstract]

Typical oil red O staining images showing the alleviation of lipid accumulation by LMY and Pitavastatin (NK-104) (2% (w/w); dietary administration) in larval zebrafish. The number of zebrafish larvae involved in each experimental group is indicated in the top left corner of each image.
FASEB J

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. [Abstract]

2026 May 15;40(9):e71873. PMID: 42087353
Proteomics

A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells. [Abstract]

2023 Aug;23(16):e2300041. PMID: 37140101

Pitavastatin purchased from MedChemExpress. Usage Cited in: Proteomics. 2023 Aug;23(16):e2300041. [Abstract]

IC₅₀ values of ERK, S6K inhibitors and statins in parental and resistant cells. (The treatment duration for compounds such as Pitavastatin was 72 h.)

Pitavastatin purchased from MedChemExpress. Usage Cited in: Proteomics. 2023 Aug;23(16):e2300041. [Abstract]

Western blot against cav-1 after treatment of resistant cells with statins at IC₅₀s for 48 h. Stained MIA PaCa-2 cells were treated with 1 µM GDC-0994, 30 µM DG2, 1.56 µM atorvastatin, 1.56 µM fluvastatin or 0.195 µM Pitavastatin.
Food Chem Toxicol

2026 Dec:218:116357. PMID: 42674150
Braz J Med Biol Res

Pitavastatin reduces intestinal fibrosis in chronic colitis and inhibits colon fibroblast activation by enhancing MMP-9 expression via the IGF-1/IGF-1R pathway. [Abstract]

2025 Aug 22:58:e14540. PMID: 40862456
Biomed Pharmacother

2026 Sep:202:119803. PMID: 42537395
bioRxiv

2026 Jun 30:2026.06.29.733236. PMID: 42427568
bioRxiv

2024 June 11.
Research Square Preprint

2024 Apr 9.

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (237.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3727 mL

11.8635 mL

23.7270 mL

5 mM

0.4745 mL

2.3727 mL

4.7454 mL

10 mM

0.2373 mL

1.1864 mL

2.3727 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (283 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Morikawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7(3):138-44. [Content Brief]

[2]. Katsuki S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation. 2014 Feb 25;129(8):896-906. [Content Brief]

[3]. Tajiri K, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013 Oct;27(5):413-24. [Content Brief]

[4]. Hamano T, et al. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging. 2012 Oct;33(10):2306-20. [Content Brief]

[5]. de Wolf E, et al.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.Sci Rep. 2017 Jul 14;7(1):5410. [Content Brief]

[6]. Demir B, et al. The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture. Cardiovasc Ther. 2019 May 2;2019:2549432. [Content Brief]

[7]. Hayashi T, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis. 2004 Oct;176(2):255-63. [Content Brief]

[8]. Sahebkar A, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021 Nov;84:101127. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3727 mL	11.8635 mL	23.7270 mL	59.3176 mL
	5 mM	0.4745 mL	2.3727 mL	4.7454 mL	11.8635 mL
	10 mM	0.2373 mL	1.1864 mL	2.3727 mL	5.9318 mL
	15 mM	0.1582 mL	0.7909 mL	1.5818 mL	3.9545 mL
	20 mM	0.1186 mL	0.5932 mL	1.1864 mL	2.9659 mL
	25 mM	0.0949 mL	0.4745 mL	0.9491 mL	2.3727 mL
	30 mM	0.0791 mL	0.3955 mL	0.7909 mL	1.9773 mL
	40 mM	0.0593 mL	0.2966 mL	0.5932 mL	1.4829 mL
	50 mM	0.0475 mL	0.2373 mL	0.4745 mL	1.1864 mL
	60 mM	0.0395 mL	0.1977 mL	0.3955 mL	0.9886 mL
	80 mM	0.0297 mL	0.1483 mL	0.2966 mL	0.7415 mL
	100 mM	0.0237 mL	0.1186 mL	0.2373 mL	0.5932 mL

Bioz

Pitavastatin

18 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Pitavastatin

Publications Citing Use of MedChemExpress (MCE) Pitavastatin